Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAO1 | Q9UJM8 | 20/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29692469 | 1.00 | HAO1 (0.66) | HAO1 | |
| SCHEMBL23001994 | 0.87 | HAO1 (0.66) | HAO1 | |
| SCHEMBL29891500 | 0.87 | HAO1 (0.66) | HAO1 | |
| SCHEMBL23002058 | 0.85 | HAO1 (0.67) | HAO1 | |
| SCHEMBL29891901 | 0.85 | HAO1 (0.67) | HAO1 | |
| SCHEMBL29692384 | 0.84 | HAO1 (0.68) | HAO1 | |
| SCHEMBL23001834 | 0.84 | HAO1 (0.68) | HAO1 | |
| SCHEMBL21296899 | 0.84 | HAO1 (0.63) | HAO1 | |
| SCHEMBL21296986 | 0.83 | HAO1 (0.53) | HAO1 | |
| SCHEMBL29692318 | 0.83 | HAO1 (0.53) | HAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2025-06-12 | — | — | US | disclosed |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2023-04-13 | — | — | US | disclosed |
| US-11504367-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-114980886-A | Compounds and methods for treating oxalate-related diseases | 奥沙鲁克斯公司 | 2022-08-30 | — | — | CN | disclosed |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | OXALURX, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| EP-4017490-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | Oxalurx, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2021-02-25 | — | — | US | disclosed |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2021-02-25 | — | — | US | disclosed |
| WO-2021035196-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| WO-2021035196-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. | 2020-12-17 | — | — | US | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| WO-2019165159-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | OXALURX, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390778-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, LOX | HAO1 14/4885 |
| US-20210052586-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | HAO1 14/4885 |
| US-11389456-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, LOX | HAO1 14/4885 |
| US-11504367-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | HAO1 14/4885 |
| US-20250186441-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | HAO1 14/4885 |
| US-20230110495-A1 | COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES | XDH, PNPO, OAT | HAO1 14/4885 |
| US-12213976-B2 | Compounds and methods for treating oxalate-related diseases | XDH, PNPO, OAT | HAO1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.